Pfizer lifts profit forecast as investors await turnaround
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Nasdaq futures drop over 2% on concerns over AI buildout costs, Fed rate outlook
- Nasdaq 100 set to shed over $1 trillion as tech selloff deepens; SpaceX slides
- Oil prices fall as investors focus on Hormuz flows after peace talks
- SpaceX slides, tech stocks dip — what’s moving markets
- Deutsche Bank cuts gold outlook as Fed repricing weighs on prices
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Pfizer (PFE) PT Raised to $34 at Goldman Sachs
July 31, 2024 5:20 AM EDTGoldman Sachs analyst Chris Shibutani raised the price target on Pfizer (NYSE: PFE) to $34.00 (from $31.00) while maintaining a Buy rating.
The analyst comments "Relative outperformance on the day (+2% vs. flat XLV) appears warranted in our view given solid 2Q results... More
